To access this material please log in or register

Register Authorize

Time-related changes in growth hormone and insulin-like growth factor 1 in blood of patients with decompensated chronic heart failure as a marker for prognosis and therapy efficacy

Dronova A. V., Sitnikova M. Yu., Grineva E. N., Shlyakhto E. V., Solntsev V. N.

Keywords: NT-fragment of brain natriuretic peptide, growth hormone, insulin-like growth factor 1, prognosis, CHF

DOI: 10.18087/rhfj.2013.6.1869

Background. Multiple clinical and laboratory tests are presently used for determining the CHF prognosis and severity. However, accurate prediction of HF course is still unfeasible. This is why searching for new predictors of life span and therapy efficacy in CHF patients has been continued. Aim. Studying serum levels of growth hormone (GH) and insulin-like growth factor 1 (ILGF-1) and their ratio (ILGF-1 / GH) in patients with CHF of ischemic origin to identify predictors of the disease course, therapy efficacy and prognosis. Materials and methods. The study included 53 men aged 47 to 75 years (main groups) who were admitted for progressive symptoms of systolic CHF (LV EF ≤45 %). The control group consisted of 13 men aged 49 to 69 years who had IHD with preserved LV EF according to echoCG data (>60 %). Results. On admission, the ILGF-1 / GH ratio was lower in patients who had FC III CHF at 6 months of follow-up than in patients, who had FC II CHF at 6 months of follow-up (р=0.02). At 6 months of follow-up, the decrease in GH level was markedly greater in patients with FC II CHF than in patients with FC III CHF (almost by two thirds and less than by half, respectively). Patients who died had had initially (at stage of decompensated CHF) significantly lower ILGR-1 / GH ratio than those who survived (р=0.01); this ratio remained the same after the condition was stabilized in the hospital (р=0.03). Conclusion. In decompensated CHF, persistence of high CHF FC at 6 months of follow-up was predicted by blood GH >1.9 mIU / l and ILGF1 / GH ratio <320. ILGF-1 / GH ratios below 130 at the stage of decompensated CHF were associated with a risk of fatal outcome in patients with FC III–IV CHF of ischemic origin. A close correlation was found between blood levels of GH and NTfragment of brain natriuretic peptide at stages of decompensated CHF, CHF stabilization, and at 6 months of hospitalization.
  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10 (10):933–989.
  2. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  3. Дронова А. В., Гринева Е. Н., Ситникова М. Ю., Шляхто Е. В. Система гормон роста – инсулиноподобный фактор роста-1 на разных этапах течения хронической сердечной недостаточности Артериальная гипертензия. 2010;16 (3):299–304.
  4. Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and ca­tabolic / anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96 (2):526–534.
  5. Jankowska EA, Biel B, Majda J et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114 (17):1829–1837.
  6. Saccà L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail. 2009;2 (2):151–156.
  7. Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc. 2003;78 (12):1521–1526.
  8. Van den Berghe G. Endocrine evaluation of patients with critical illness. Endocrinol Metab Clin North Am. 2003;32 (2):385–410.
  9. Sacca L. Growth hormone: a newcomer in cardiovascular medicine. Cardiovasc Res. 1997;36 (1):3–9.
  10. Friberg L, Werner S, Eggertsen G, Ahnve S. Growth hormone and insulin-like growth factor-1 in acute myocardial infarction. Eur Heart J. 2000;21 (18):1547–1554.
  11. Petretta M, Colao A, Sardu C et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res. 2007;17 (4):288–296.
  12. Nagaya N, Uematsu M, Kojima M et al. Elevated circulating level of grelin in cachexia associated with chronic heart failure relationships between grelin and anabolic / catabolic factors. Circulation. 2001;104 (17):2034–2038.
  13. Yamaguchi H, Komamura K, Choraku M et al. Impact of serum insulin-like growth factor-1 on early prognosis in acute myocardial infarction. Intern Med. 2008;47 (9):819–825.
  14. Schneider HJ, Klotsche J, Saller B et al. Associations of age-dependent IGF-1 SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur J Endocrinol. 2008;158 (2):153–161.
  15. Colao A. The GH-IGF-1 axis and the cardiovascular system: clinical implication. Clin Endocrinol (Oxf). 2008;69 (3):347–358.
  16. Bondanelli M, Ambrosio MR, Onofri A et al. Predictive value of circulating insulin-like growth factor 1 as levels in ischemic stroke outcome. J Clin Endocrinol Metab. 2006;91 (10):3928–3934.
  17. Lee WL, Chen JW, Ting CT et al. Changes of the insulin-like growth factor I system during acute myocardial infarction: implications on left ventricular remodeling. J Clin Endocrinol Metab. 1999;84 (5):1575–1581.
  18. Anversa P. Aging and longevity: the IGF-1 enigma. Circ Res. 2005;97 (5):411–414.
Dronova A. V., Sitnikova M. Yu., Grineva E. N. et al. Time-related changes in growth hormone and insulin-like growth factor 1 in blood of patients with decompensated chronic heart failure as a marker for prognosis and therapy efficacy. Russian Heart Failure Journal. 2013;14 (6):329-333

To access this material please log in or register

Register Authorize
Ru En